quant Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (Nifty Healthcare TRI) is not available to us as a series.
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| TREPS 01-Sep-2026 DEPO 10 | — | 22.66% | — | — |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | 10.58% | — | 44.3 |
| Zydus Lifesciences Limited | Healthcare | 9.30% | — | 33.3 |
| Pfizer Ltd | Healthcare | 8.83% | — | 24.1 |
| Alivus Life Sciences | Healthcare | 8.08% | — | 28.1 |
| Concord Biotech Limited | Healthcare | 7.03% | — | 51.0 |
| SMS Pharmaceuticals Limited | Healthcare | 6.71% | — | 47.9 |
| IPCA Laboratories Ltd | Healthcare | 6.22% | — | 39.3 |
| Zydus Wellness Ltd | Fast Moving Consumer Goods | 5.64% | — | 423.8 |
| Aurobindo Pharma Limited | Healthcare | 5.18% | — | 37.4 |
| Strides Pharma Science Ltd | Healthcare | 2.45% | — | 42.5 |
| 91 Days Treasury Bill 03-Sep-2026 | — | 0.70% | — | — |
| 91 Days Treasury Bill 10-Sep-2026 | — | 0.70% | — | — |
| 91 Days Treasury Bill 17-Sep-2026 | — | 0.70% | — | — |
| 91 Days Treasury Bill 15-Oct-2026 | — | 0.70% | — | — |
| 91 Days Treasury Bill 22-Oct-2026 | — | 0.70% | — | — |
| 91 Days Treasury Bill 05-Nov-2026 | — | 0.69% | — | — |
| 91 Days Treasury Bill 19-Nov-2026 | — | 0.69% | — | — |
| 91 Days Treasury Bill 27-Nov-2026 | — | 0.69% | — | — |
| Sumitomo Chemical India Limited | Chemicals | 0.31% | — | 37.3 |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 2.40% · Nov 25 2.40% · Dec 25 2.42% · Jan 26 2.42% · Feb 26 2.42% · Mar 26 2.42% · Apr 26 2.47% · May 26 2.47% · Jun 26 3.01% · Jul 26 3.14% · Aug 26 3.12% · Sep 26 3.13%
For redemptions / switch outs (including SIP/STP) within; 15 days from the date of allotment of units, irrespective of the; amount of investment: 1%; No exit load shall be applicable on switches from Regular Plan to; Direct Plan and vice versa, under the same scheme.
The investment objective of the scheme is to seek long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. There is no assurance that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
